Ashwagandha Compound Withanolide B Shows Potent Selective Kill of Lung Cancer Cells
Withanolide B from ashwagandha targets AKT signaling in NSCLC, killing cancer cells at 5 μM while sparing normal lung tissue.
Summary
Researchers investigated Withanolide B (WB), a bioactive compound from ashwagandha (Withania somnifera), as a potential treatment for non-small cell lung cancer (NSCLC). Using computer modeling and laboratory experiments, they found WB binds strongly to all three AKT protein isoforms — key drivers of cancer cell survival. In lung cancer cells (A549), WB had an IC50 of just 5 μM, triggering harmful reactive oxygen species buildup, mitochondrial damage, programmed cell death, and cell cycle arrest. Critically, normal lung epithelial cells were largely spared, suggesting cancer-selective activity. While direct measurement of AKT inhibition was not performed, the combined computational and functional evidence is promising. The findings support further preclinical and eventual clinical investigation of this traditional herb-derived compound.
Detailed Summary
Non-small cell lung cancer (NSCLC) is the leading cause of cancer death worldwide, and resistance to existing therapies remains a major clinical challenge. The PI3K/AKT signaling pathway is among the most frequently dysregulated survival pathways in NSCLC, making it an attractive drug target. This study explores whether Withanolide B (WB), a steroidal lactone from the Ayurvedic adaptogen ashwagandha (Withania somnifera), can selectively inhibit this pathway.
Researchers employed a dual in silico and in vitro strategy. Molecular docking and 100-nanosecond molecular dynamics simulations were performed to assess how WB interacts with all three AKT isoforms (AKT1, AKT2, AKT3). Binding free energies were calculated using MM-PBSA analysis, and drug-likeness plus toxicity were predicted computationally. Laboratory experiments were then conducted in A549 NSCLC cells and L132 normal lung epithelial cells.
Computationally, WB showed stable binding across all AKT isoforms, with especially favorable energetics at AKT2. In cell culture, WB reduced A549 viability with an IC50 of 5 μM — a potent result. Mechanistically, treatment induced reactive oxygen species accumulation, loss of mitochondrial membrane potential, chromatin condensation, apoptosis, and S-phase cell cycle arrest. Importantly, normal L132 lung epithelial cells showed markedly less sensitivity, pointing to tumor-selective cytotoxicity.
For the longevity and cancer-health audience, these findings are significant on two levels. First, they provide mechanistic grounding for ashwagandha's traditional anticancer reputation. Second, targeting AKT — a pathway also implicated in cellular aging, insulin resistance, and senescence — may offer broader healthspan relevance beyond oncology.
Key caveats apply. Direct biochemical confirmation of AKT phosphorylation inhibition was not performed, so the mechanistic link remains partly inferred. The study used only one cancer cell line. All data are preclinical; human translation requires substantially more investigation. The summary is based on the abstract only.
Key Findings
- Withanolide B killed NSCLC cells at an IC50 of just 5 μM while largely sparing normal lung epithelial cells.
- WB induced ROS accumulation, mitochondrial depolarization, apoptosis, and S-phase cell cycle arrest in lung cancer cells.
- Computational modeling showed stable, energetically favorable binding of WB to all three AKT isoforms, especially AKT2.
- Integrated in silico and in vitro evidence supports WB as a multi-isoform AKT modulator with drug-like properties.
- Findings provide mechanistic backing for ashwagandha's traditional anticancer use and warrant further preclinical study.
Methodology
The study combined molecular docking, 100-ns molecular dynamics simulations, and MM-PBSA free-energy calculations with in vitro assays in A549 NSCLC and L132 normal lung epithelial cells. Cell-based endpoints included MTT viability, ROS quantification, mitochondrial membrane potential, apoptosis staining, and cell cycle profiling. Drug-likeness and toxicity were assessed computationally via SwissADME and DataWarrior.
Study Limitations
Direct biochemical evidence of AKT phosphorylation inhibition was not obtained, so the proposed mechanism remains partially inferred from functional assays and computational data. The in vitro work used a single NSCLC cell line (A549), limiting generalizability. The summary is based on the abstract only, as the full paper was not accessible.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: